PHASE I STUDY OF ROMIDEPSIN AND LIPOSOMAL DOXORUBICIN IN RELAPSED OR REFRACTORY T‐CELL LYMPHOMA

Weiyun Z. Ai(City College of San Francisco), Jonathan E. Brammer(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Khoan Vu(University of California, San Francisco), Pierluigi Porcu(Thomas Jefferson University), Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), B. Andreadis(University of California, San Francisco), Laura Pincus(University of California, San Francisco)
Hematological Oncology
June 1, 2019
10.1002/hon.147_2630
Cited by 0

Related Papers

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428